Biogen Inc. $BIIB Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 8.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,255,168 shares of the biotechnology company’s stock after selling 122,400 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Biogen were worth $271,192,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in BIIB. Rothschild Investment LLC grew its position in shares of Biogen by 12.3% in the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 56 shares during the period. Meeder Advisory Services Inc. lifted its position in Biogen by 1.2% during the first quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock worth $866,000 after buying an additional 57 shares during the period. Kera Capital Partners Inc. lifted its position in Biogen by 3.5% during the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock worth $316,000 after buying an additional 58 shares during the period. Parallel Advisors LLC boosted its stake in Biogen by 1.5% in the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after buying an additional 65 shares during the last quarter. Finally, Itau Unibanco Holding S.A. boosted its stake in Biogen by 24.4% in the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after buying an additional 66 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Performance

Biogen stock opened at $216.65 on Tuesday. The stock’s 50-day moving average is $208.15 and its 200-day moving average is $195.89. The company has a market cap of $32.01 billion, a price-to-earnings ratio of 38.35, a price-to-earnings-growth ratio of 6.81 and a beta of 0.17. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. Biogen Inc. has a 12 month low of $131.52 and a 12 month high of $222.85.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The company’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities analysts anticipate that Biogen Inc. will post 12.39 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BIIB shares. Truist Financial raised shares of Biogen from a “hold” rating to a “buy” rating and upped their price objective for the company from $190.00 to $235.00 in a research note on Monday, July 13th. Barclays raised their target price on shares of Biogen from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 29th. Piper Sandler restated an “overweight” rating on shares of Biogen in a report on Tuesday, July 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biogen in a research report on Monday, June 22nd. Finally, HC Wainwright increased their price target on shares of Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $227.79.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.